California Doc Loses DEA Badge: No More Controlled Drug Handling
Published Date: 6/26/2025
Notice
Summary
Dr. Bohdan Olesnicky from California lost his DEA registration because he no longer has permission to handle controlled substances in his state. He didn’t ask for a hearing to challenge this, so the DEA officially revoked his registration starting in 2025. This means he can’t legally prescribe or handle certain drugs anymore, affecting his medical practice and patients.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 2 costs, 0 mixed.
DEA Registration Revoked July 28, 2025
The Drug Enforcement Administration revoked Bohdan Olesnicky, M.D.'s DEA Certificate of Registration No. FO0628391, effective July 28, 2025. Because Dr. Olesnicky surrendered his California medical license on December 5, 2023, he is not authorized to prescribe or handle controlled substances in California and may not legally dispense those drugs.
Pending DEA Applications Denied in California
The Order also denies any pending applications by Bohdan Olesnicky, M.D., to renew or modify Certificate of Registration No. FO0628391 and denies any other pending applications for additional DEA registration in California. This denial is part of the same Order that takes effect July 28, 2025.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20226, By Grace Inc. Counseling Services; Decision and Order
By Grace Inc. Counseling Services in Baltimore faced losing its DEA license because it didn’t keep good records and lied about its owner’s past drug conviction. After a hearing, the DEA decided to revoke their registration, meaning they can’t legally handle controlled substances anymore. This affects the clinic’s ability to operate and could impact patients relying on their services.
2026-20227, St. Michael's Pharmacy; Decision and Order
St. Michael's Pharmacy in Texas had its DEA license suspended and is facing revocation because it kept filling risky drug prescriptions without fixing obvious warning signs of abuse. This affects the pharmacy’s ability to legally handle controlled substances and could impact patients relying on it. The pharmacy must now deal with these serious legal actions, which started in late 2025 and could lead to permanent closure or fines.
Previous / Next Documents
Previous: 2025-11496, Agency Information Collection Activities; Proposed Collection; Comment Request; Office of Foreign Assets Control Reporting, Procedures and Penalties Regulations Sanctions Reconsideration Portal
The Treasury Department wants your thoughts on a new online tool called the Sanctions Reconsideration Portal, which will make it easier to handle sanctions reports and appeals. This change affects anyone dealing with OFAC sanctions rules and aims to cut down on paperwork and hassle. You’ve got a chance to weigh in before the plan moves forward—no extra costs, just smoother processes!
Next: 2025-11730, Agency Information Collection Activities; Notice and Request for Comment; Generic Clearance for the Collection of Qualitative Feedback on Agency Service Delivery
NHTSA wants your thoughts on how they collect feedback about their services. They’re asking for approval to keep gathering this info in a simple, easy way that helps them improve. If you use or interact with their services, this could affect you, and they’re open for comments now before they get the green light.